–
Israeli Stem cell developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) and Korea’sCHA Bio&Diostech (Kodaq: CHA) are moving forward with the strategic partnership agreement reached in June 2013.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Pluristem and CHA entered into investment agreements pursuant to which Pluristem has issued to CHA 2, 500, 000 shares of its common stock in consideration for the issuance to Pluristem of 1, 011, 504 shares of CHA.
This reflects a total consideration of $10.4 million, at a price of $4.16 per Pluristem common share, a premium of 26% over the closing price on December 16, 2013. The shares are subject to a lock up period of one year.
The previously announced agreement with CHA encompasses the use of Pluristem’s PLX-PAD cells in the treatment of two subsets of Peripheral Artery Disease (PAD) in South Korea: Intermittent Claudication (IC) and Critical Limb Ischemia (CLI).
Zami Aberman, Pluristem’s Chairman and CEO stated, “We believe that initiating clinical trials with CHA Bio for indications in the area of peripheral vascular disease opens significant opportunities for Pluristem in South Korea’s dynamic regenerative medicine industry.”
The first clinical study to be performed as part of the agreement will be a Phase II trial in IC which will run in parallel to the Phase II trial being conducted in the USA, Germany and Israel.
This study was already approved in November 2013 by South Korea’s Ministry of Food and Drug Safety (MFDS).
Pluristem and CHA Bio will establish a joint venture (JV) co-owned by the parties to commercialize PLX cell products in South Korea. Additionally, Pluristem will be able to use the data generated by CHA Bio to pursue the development of PLX product candidates outside of South Korea.
